Related Experiment Videos
MTX affects inflammation and tissue destruction differently in the rat AA model
S L Morgan1, J E Baggott, W K Bernreuter
1Department of Nutrition Sciences, University of Alabama at Birmingham, 35294-3360, USA. slmorgan@uabl.edu
The Journal of Rheumatology
|July 27, 2001
Summary
Methotrexate (MTX) therapy for rat adjuvant arthritis (AA) showed that while higher doses reduced tissue destruction, inflammation suppression peaked at 1 mg/week. Higher MTX doses caused toxicity and reduced anti-inflammatory effects.
Area of Science:
- Pharmacology
- Immunology
- Veterinary Medicine
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Adjuvant arthritis (AA) in rats serves as a common animal model for RA research.
- Methotrexate (MTX) is a widely used disease-modifying antirheumatic drug (DMARD) for RA.
Purpose of the Study:
- To determine the dose-response relationship of methotrexate (MTX) in a rat model of adjuvant arthritis (AA).
- To evaluate the efficacy and toxicity of varying MTX doses in suppressing arthritis progression.
- To understand the differential effects of MTX on inflammation and tissue destruction in AA.
Main Methods:
- Female Lewis rats were administered weekly doses of MTX (0, 0.3, 1, 2, 3, 5, and 10 mg).
- Arthritis severity was assessed using hindpaw edema, ankle width measurements, and radiographic and histopathologic scoring.
- Treatment duration was 6 weeks, commencing 3 days post-adjuvant injection.
Main Results:
- Higher MTX doses (2-10 mg/week) led to mortality and suppressed body weight gain.
- MTX demonstrated a dose-dependent reduction in tissue destruction.
- Maximal suppression of inflammation occurred at 1 mg/week MTX, with decreased efficacy at higher doses.
Conclusions:
- The anti-inflammatory and tissue-protective effects of MTX in rat AA are not dose-dependent in a straightforward manner.
- Increasing MTX doses beyond 1 mg/week resulted in toxicity without further enhancing inflammation suppression.
- The findings suggest a complex dose-response dynamic for MTX in AA, with implications for RA treatment strategies.